Department of Immunology, School of Medicine, UASLP, San Luis Potosí, México.
Trends Mol Med. 2013 Oct;19(10):625-32. doi: 10.1016/j.molmed.2013.07.006. Epub 2013 Aug 13.
Early studies described CD69 as a leukocyte activation marker, and suggested its involvement in the activation of different leukocyte subsets as well as in the pathogenesis of chronic inflammation. However, recent investigations have showed that CD69 knockout mice exhibit an enhanced or reduced susceptibility to different experimental models of inflammatory diseases, including those mediated by T helper 17 (Th17) lymphocytes. In this regard, the expression of CD69, both in Th17 lymphocytes and by a subset of regulatory T cells, has an important role in the control of the immune response and the inflammatory phenomenon. Therefore, different evidence indicates that CD69 exerts a complex immunoregulatory role in humans, and that it could be considered as a target molecule for the therapy of immune-mediated diseases.
早期研究将 CD69 描述为白细胞活化标志物,并提示其参与不同白细胞亚群的活化以及慢性炎症的发病机制。然而,最近的研究表明,CD69 敲除小鼠对不同的炎症性疾病实验模型表现出增强或减弱的易感性,包括由辅助性 T 细胞 17(Th17)淋巴细胞介导的疾病。在这方面,CD69 的表达,无论是在 Th17 淋巴细胞中还是在调节性 T 细胞的一个亚群中,都在控制免疫反应和炎症现象中发挥着重要作用。因此,不同的证据表明,CD69 在人类中发挥着复杂的免疫调节作用,并且可以将其视为免疫介导性疾病治疗的靶标分子。